Calcium Pyrophosphate Deposition DiseasePYC-OMICNCT07005804
Calcium Pyrophosphate Deposition (CPPD) Disease
A study testing transcriptomic and metabolomic analysis in people with Calcium Pyrophosphate Deposition Disease and Rheumatic Diseases, run by Lille Catholic University at 1 site in France.
Trial summary
The goal of this clinical trial is to describe the transcriptomic and metabolomic profile of patients with chronic Calcium Pyrophosphate Deposition (CPPD) compared to those with acute CPPD. Read more about this study
- Who is it for?
- Ages 65 years and older
- Conditions the study is for
- Calcium Pyrophosphate Deposition Disease, Rheumatic Diseases
- What is being tested?
- transcriptomic and metabolomic analysis
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 137 participants
- Where
- 1 siteFrance
- Study dates
- Oct 2025to Nov 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 65 years and older
- All sexes
- No healthy volunteers
- Older adult
Who may be able to join
None listed.
Who cannot join
- Missing data concerning transcriptomic and metabolomic analyses.
- Opposition
- History of gout or presence of monosodium urate (MSU) crystals on joint fluid,
- Cognitive decline (confusion and neurodegenerative diseases)
- Inability to provide informed consent and disease VAS
- Patient under guardianship or curatorship
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site
Hôpital Saint-Philibert (GHICL)
Lomme, 59160
Charlotte JAUFFRET, +333 20 22 50 59, jauffret.charlotte@ghicl.net
About this study
Official title: Calcium Pyrophosphate Deposition (CPPD) Disease : Clinical and Paraclinical Profile, Gene Expression and Metabolomics of the Acute and Chronic Clinical Phenotype
The goal of this clinical trial is to describe the transcriptomic and metabolomic profile of patients with chronic Calcium Pyrophosphate Deposition (CPPD) compared to those with acute CPPD.
The hypotheses are as follows :
Read more
- It is hypothesised that there is a transcriptomic and metabolomic signature of CPPD which explains why therapeutic responses to different anti-inflammatory treatments differ from one phenotype to another one
- It is hypothesised that the acute and chronic clinical phenotypes of CPPD have different clinical, biological and imaging characteristics, as well as a differing predisposition toward crystalline deposition and inflammatory pathway activation.
The management of participants with chronic forms of the disease included in this research was modelled on the usual recommended management, including a biological workup, joint puncture, ultrasound and radiographic workup. Double-energy CT scans and transcriptomic and metabolomic analyses on plasma are not routine tests.
- Being tested
- transcriptomic and metabolomic analysis
- Keywords
- Calcium pyrophosphate deposition disease, gene expression, acute clinical phenotype, chronic clinical phenotype, metabolic expression
- Medical subject headings
- Chondrocalcinosis, Rheumatic Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
transcriptomic and metabolomic analysisGenetic
Venous blood samples for transcriptomic and metabolomic analysis will be taken in 3 x 4 mL ethylenediaminetetraacetic acid (EDTA) tubes and stored immediately at 4°C, before being cryopreserved at -80°C in 500 μL aliquots of plasma. In addition, for transcriptomic analysis, a sample will also be taken in a Paxgen RNA tube cryopreserved at -80°C.
| Study group | Role | What they receive |
|---|---|---|
| Patients with a chronic CPPD | Experimental | Patients with diagnosis of chronic calcium pyrophosphate crystal arthritis (either acute recurrent or persistent arthritis), meeting the 2023 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification criteria, after evaluation by a rheumatologist from the rheumatology department. Receives: Genetic: transcriptomic and metabolomic analysis |
What is being measured
The primary outcome is the main question the study is designed to answer.
Transcriptomic profile
-Quantitative transcriptomic profiling (expression of the genes involved) and qualitative profiling (analysis of the sequence of variants expressed)
Measured: 2 weeks
Metabolomic profile
- Metabolomic profile: quantitative assessment of the metabolites involved in each phenotype, then qualitatively grouped by activated metabolic pathway
Measured: 2 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Jun 2025
- Study startOct 2025 (estimated)
- Primary completionMay 2027 (estimated)
- Study completionNov 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Calcium Pyrophosphate Deposition DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- The PYC-OMIC study is a prospective, single-centre, cross-sectional, comparative study of chronic versus acute forms of CPPD. It is an interventional study with minimal risks and constraints for chronic forms recruited prospectively. Acute forms are included retrospectively.
- Masking
- None (open label)
- Enrolment
- 137 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Lille Catholic University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Charlotte JAUFFRET, Principal investigator, Rheumatology Department - Hôpital Saint-Vincent - GHICL
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07005804
- Sponsor's protocol ID
- RC-P00127
- Acronym
- PYC-OMIC
- Status last verified
- May 2025
- First submitted
- 26 May 2025
- Last updated
- 5 Jun 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 5 Jun 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Calcium Pyrophosphate Deposition (CPPD) Disease : Clinical and Paraclinical Profile, Gene Expression and Metabolomics of the Acute and Chronic Clinical Phenotype
- ClinicalTrials.gov ID
- NCT07005804
- Acronym / sponsor ID
- PYC-OMIC / RC-P00127
- Keywords
- Calcium pyrophosphate deposition disease, gene expression, acute clinical phenotype, chronic clinical phenotype, metabolic expression
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 137 participants (estimated)
- Lead sponsor
- Lille Catholic UniversityUniversity, hospital or other
- Study start
- Oct 2025 (estimated)
- Primary completion
- May 2027 (estimated)
- Study completion
- Nov 2027 (estimated)
- First posted
- 5 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to describe the transcriptomic and metabolomic profile of patients with chronic Calcium Pyrophosphate Deposition (CPPD) compared to those with acute CPPD.
The hypotheses are as follows :
- It is hypothesised that there is a transcriptomic and metabolomic signature of CPPD which explains why therapeutic responses to different anti-inflammatory treatments differ from one phenotype to another one
- It is hypothesised that the acute and chronic clinical phenotypes of CPPD have different clinical, biological and imaging characteristics, as well as a differing predisposition toward crystalline deposition and inflammatory pathway activation.
The management of participants with chronic forms of the disease included in this research was modelled on the usual recommended management, including a biological workup, joint puncture, ultrasound and radiographic workup. Double-energy CT scans and transcriptomic and metabolomic analyses on plasma are not routine tests.
Study design
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- The PYC-OMIC study is a prospective, single-centre, cross-sectional, comparative study of chronic versus acute forms of CPPD. It is an interventional study with minimal risks and constraints for chronic forms recruited prospectively. Acute forms are included retrospectively.
| Arm | Type | Receives |
|---|---|---|
| Patients with a chronic CPPD | Experimental | Genetic: transcriptomic and metabolomic analysisPatients with diagnosis of chronic calcium pyrophosphate crystal arthritis (either acute recurrent or persistent arthritis), meeting the 2023 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification criteria, after evaluation by a rheumatologist from the rheumatology department. |
Who may qualify
- Ages
- 65 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
Key inclusion criteria (0 listed)
Key exclusion criteria (6 listed)
- Missing data concerning transcriptomic and metabolomic analyses.
- Opposition
- History of gout or presence of monosodium urate (MSU) crystals on joint fluid,
- Cognitive decline (confusion and neurodegenerative diseases)
- Inability to provide informed consent and disease VAS
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| transcriptomic and metabolomic analysisVenous blood samples for transcriptomic and metabolomic analysis will be taken in 3 x 4 mL ethylenediaminetetraacetic acid (EDTA) tubes and stored immediately at 4°C, before being cryopreserved at -80°C in 500 μL aliquots of plasma. In addition, for transcriptomic analysis, a sample will also be taken in a Paxgen RNA tube cryopreserved at -80°C. | Genetic | Patients with a chronic CPPD |
Primary outcome
Transcriptomic profile
Time frame: 2 weeks
-Quantitative transcriptomic profiling (expression of the genes involved) and qualitative profiling (analysis of the sequence of variants expressed)
Metabolomic profile
Time frame: 2 weeks
- Metabolomic profile: quantitative assessment of the metabolites involved in each phenotype, then qualitatively grouped by activated metabolic pathway
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Jun 2025.
- Individual participant dataSharing planned: No
Related trials for Calcium Pyrophosphate Deposition Disease
Active, not recruiting
Efficacy and Safety of Digital Therapeutics for Improving Shoulder Function After Rotator Cuff Repair
Rotator Cuff Tear Arthropathy, Repair of a Cuff Tear
Enrolling by invitationPhase 1
Stem Cell Treatment for Regeneration of the Rotator Cuff (Lipo-Cuff Study)
Rotator Cuff Tears, Rotator Cuff Injuries
RecruitingPhase 2
Colchicine to Reduce Your SympToms And Lower Levels of Inflammation, Zeroing in on Effective CPPD Disease Treatment
CPPD - Calcium Pyrophosphate Deposition Disease
RecruitingObservational study
Exactech Shoulder Post Market Clinical Follow-up Study
Osteo Arthritis Shoulders, Osteonecrosis
RecruitingObservational study
Perform Humeral System Study
Osteoarthritis Shoulder, Avascular Necrosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Charlotte JAUFFRET principal investigator
Rheumatology Department - Hôpital Saint-Vincent - GHICL
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing transcriptomic and metabolomic analysis in people with Calcium Pyrophosphate Deposition Disease and Rheumatic Diseases, run by Lille Catholic University at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 0 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 5 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Marie Paule LEBITASY (+333 20 22 57 41, Lebitasy.Marie-Paule@ghicl.net), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Transcriptomic profile (time frame: 2 weeks). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Jun 2025.